Valneva's Lyme disease
vaccine candidate - VLA15

Valneva has developed a multivalent, protein subunit based vaccine candidate against Lyme disease.


In December 2016, Valneva initiated a Phase I trial in the US and Europe, following clearance from the Food & Drug Administration (FDA) and the Belgian authorities, that will include 180 subjects. The first patient was vaccinated at the end of January 2017.

Pre-clinical data showed that this vaccine candidate has the potential for protection against the majority of Borrelia species pathogenic for humans (Source).

In 2017, the company will advance the Phase I trial of its Lyme vaccine candidate and expects to accelerate the program´s progression towards Phase II.

Valneva’s program is the only active vaccine development program for Lyme disease in the pharmaceutical industry.

Download:
Lyme Disease - A tick-transmitted infection (brochure)
Webcast of Key Opinion Leader Event: DEVELOPING A VACCINE FOR LYME DISEASE


About Lyme borreliosis




This program is supported by the Vienna Business Agency.

Wirtschaftsagentur Wien
Please update your browser...